WallStreetZenWallStreetZen

NASDAQ: EXEL
Exelixis Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Exelixis earnings were $677.9M for the trailing 12 months ending Sep 30, 2025, with 55.7% growth year over year. The latest EXEL earnings report on Sep 30, 2025 announced Q3 2025 earnings of $193.6M, up 4.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EXEL reported annual earnings of $521.3M, with 150.9% growth. The next EXEL earnings date is Feb 10, 2026.

EXEL past earnings growth

How has EXEL's earnings growth performed historically?

Company
55.7%
Industry
60.05%
Market
55.47%
EXEL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
EXEL's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
EXEL's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

EXEL earnings history

Current Revenue
$2.3B
Current Earnings
$677.9M
Current Profit Margin
29.6%

EXEL Return on Equity

Current Company
31.6%
Current Industry
-21.2%
Current Market
35.1%
EXEL's Return on Equity (31.6%)... subscribe to Premium to read more.
High Return on Equity Performance

EXEL Return on Assets

Current Company
24%
Current Industry
-8.8%
EXEL is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when EXEL announces earnings.

EXEL Return on Capital Employed

Current Company
35.65%
Current Industry
-3.5%
EXEL has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

EXEL vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
EXEL$927.60M$677.90M+37.53%$2.46
MDGL-$268.42M-$289.13MN/A-$12.89
RNA-$542.90M-$549.79MN/A-$4.19
BMRN$772.70M$520.42M-10.40%$2.72
SMMT-$912.81M-$921.62MN/A-$0.01
View Top Biotech Stocks

EXEL earnings dates

Next earnings date
Feb 10, 2026

Exelixis Earnings Reports & History FAQ

What were Exelixis's earnings last quarter?

On EXEL's earnings call on Invalid Date, Exelixis (NASDAQ: EXEL) reported Q3 2025 earnings per share (EPS) of $0.72, up 75.61% year over year. Total EXEL earnings for the quarter were $193.58 million. In the same quarter last year, Exelixis's earnings per share (EPS) was $0.41.

If you're new to stock investing, here's how to buy Exelixis stock.

When does Exelixis report earnings?

The next EXEL earnings call is Invalid Date. Add EXEL to your watchlist to be reminded of Exelixis's next earnings date.

Is Exelixis profitable or losing money?

As of the last Exelixis earnings report, Exelixis is currently profitable. Exelixis's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $677.90 million, a 45.18% increase year over year.

What was EXEL's earnings growth in the past year?

As of Exelixis's earnings date in Invalid Date, Exelixis's earnings has grown 55.7% year over year. This is 4.35 percentage points lower than the US Biotechnology industry earnings growth rate of 60.05%. EXEL earnings in the past year totalled $677.90 million.

What are Exelixis's earnings expectations?

The current EPS estimate for Exelixis's earnings report in Invalid Date is $0.80.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.